Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany.

Sanofi is a global healthcare company. Among their duties are researching disease causes, determining starting points for drug treatment, developing drugs, producing active ingredients, and delivering finished drugs and active ingredients. Specialists in vaccines, rare diseases, rare blood disorders, neurology, immunology, oncology, diabetes, cardiovascular diseases, and consumer healthcare.

Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. It operates through the following segments: Small Molecules, Biologics, Branded Formulations, and Research Services. The Small Molecules segment manufactures spanning statins, immunosuppressants, antifungals, anti-obesity, anti-diabetics, ophthalmologicals, oncologicals, and urologicals etc. The Biologics segment provides Insulins and Analogs, biosimilar Monoclonal Antibodies (MAbs), and recombinant proteins The Branded Formulation segment consists of therapeutic areas of diabetology, oncology, immunology and critical care. The Research Services segment covers Syngene development platforms. The company was founded by Kiran Mazumdar-Shaw on November 29, 1978 and is headquartered in Bangalore, India.

Manufactures insulin and industrial enzymes

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

Aventis Pharma Deutschland GmbH produces pharmaceutical products. It offers prescription drugs, human vaccines, and therapeutic proteins businesses. Aventis Pharma Deutschland plans and designs plants and process control systems in the areas of active ingredients production and finished drugs. The company is headquartered in Frankfurt am Main, Germany.

Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. Its product pipelines include: Biochaperone Lispro, Combo, M1pram, Glucagon, Gla Glp-1, Glucagon Glp-1 & Cell Therapy. The company was founded by Gérard Soula, Olivier Soula and Rémi Soula on December 16, 2005 and is headquartered in Lyon, France.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

DreaMed Diabetes is a medical device, SaaS company providing personalized diabetes treatment optimization solutions. The company was established in 2014, commercializing the first artificial pancreas technology which was published in the NEJM. Eversince, DreaMed Diabetes has been vigorously working on decision support tools in the diabetes management space and became the first and only company in the world to receive FDA clearance for a decision support system using data from CGM/SMBG and insulin pumps. We offer a clinically proven decision support system for insulin titration in type 1 diabetes patients. Our Advisor Pro software was created by diabetes professionals and is based on real-world experience, turbo-charged by artificial intelligence. Using it, any healthcare professional can analyze patient data in seconds and advise on the optimal treatment plan. By frequent titration changes and online monitoring, we allow patients better treatment thus by lowering their A1C levels and risk for complications. Using the Advisor Pro physicians and nurses can provide true patient-centered care and everyone can receive the same top-level of treatment – wherever they are and whoever their caregiver is.

Abbott Diabetes Care, Inc. manufactures glucose monitoring equipments. It designs, develops and manufactures glucose monitoring systems and test strips for use in both home and hospital settings. The company was founded on August 29, 2005 and is headquartered in Abbott Park, IL.

Akzo Nobel NV is a holding company, which engages in the manufacture and sale of coating and paint products. engages in the production and marketing of paints and coatings. It operates through the following segments: Decorative Paintings, Performance Paintings, and Corporate and Others. The Decorative Paints segment manufactures and supplies a range of interior and exterior decoration and protection products for professional and do-it-yourself markets. The Performance Coatings segment produces automotive and aerospace; industrial; marine and protective; and powder coatings. The company was founded in 1792 and is headquartered in Amsterdam, Netherlands.

Scios Inc. is a pharmaceutical company developing drugs for the treatment of cardiovascular and inflammatory diseases. The company is a subsidiary of Johnson & Johnson. The company’s portfolio of drugs includes NatrecorO, a promising drug for heart failure. Scios Inc. was founded in 1981 and is based in California.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT.

Savient Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

Xencor provides protein engineering technology platforms in the biotechnology industry. Its products include antibody therapeutics, such as XmAb2513 for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma; XmAb5574, a humanized monoclonal antibody that targets the antigen CD19 for the treatment of B cell malignancies; XmAb5592 for the treatment of myeloma; and XmAb5871 and XmAb7195, which are humanized monoclonal antibodies for the treatment of asthma and allergy. The company’s products also include XPro protein therapeutics, such as XPro1595, a dominant-negative inhibitor for the treatment of multiple animal models of autoimmune and neuroinflammatory diseases.

GenVec, Inc. (NASDAQ: GNVC) GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).